Unicure Remedies Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Unicure Remedies Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $691.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unicure Remedies Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $691.7K Trade | TransData Nexus

Unicure Remedies Private Limited

Indian Pharmaceutical Exporter · Diuretics Specialist · $691.7K Total Trade · DGFT Verified

Unicure Remedies Private Limited is an Indian pharmaceutical exporter with a total trade value of $691.7K across 4 products in 3 therapeutic categories. Based on 73 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Spironolactone ($518.5K), Digoxin ($82.0K), Azathioprine ($45.8K).

Unicure Remedies Private Limited — Export Portfolio & Destination Treemap

Unicure Remedies Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Unicure Remedies Private Limited? — Company Overview & Market Position

Unicure Remedies Private Limited, established on March 3, 1993, is a privately held pharmaceutical company headquartered in Vadodara, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24230GJ1993PTC019076. As of the latest available data, Unicure Remedies has an authorized capital of ₹4.50 crore and a paid-up capital of ₹2.48 crore. The company employs approximately 351 professionals. The registered office is located at F/25, B I D C Industrial Estate, Gorwa, Vadodara, Gujarat, 390016.

What Does Unicure Remedies Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Spironolactone$518.5K 2Digoxin$82.0K

Product Portfolio — Top 4 by Export Value

Unicure Remedies Private Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Spironolactone	Diuretics	$518.5K	40	0.3%	14
2	Digoxin	Cardiovascular	$82.0K	21	3.8%	3
3	Azathioprine	Immunosuppressants	$45.8K	6	0.1%	12
4	Warfarin	Cardiovascular	$45.5K	6	0.6%	12

Unicure Remedies Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $691.7K. The top category is Diuretics (74.9% of portfolio), followed by Cardiovascular (18.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Unicure Remedies Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Unicure Remedies operates a manufacturing facility situated in the B I D C Industrial Estate in Vadodara, Gujarat. The plant specializes in the production of various pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is designed to meet both domestic and international market demands. The company emphasizes adherence to international quality standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at Unicure Remedies Private Limited includes:

Virag Parimal Divanji: Director since March 3, 1993.

Jayurbhai Ramanbhai Patel: Director since March 14, 2013.

Rahul Mansukhbhai Desai: Chief Financial Officer (CFO) since April 1, 2023.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Unicure Remedies Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Unicure Remedies Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a range of pharmaceutical formulations, such as Spironolactone, Digoxin, Azathioprine, and Warfarin, across these regions. Specific regulatory filings, approvals, and market access statuses are not publicly disclosed. However, the company's adherence to international quality standards suggests compliance with the regulatory requirements of these markets.

2Emerging Markets

Unicure Remedies Private Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's export portfolio includes formulations such as Spironolactone, Digoxin, Azathioprine, and Warfarin, catering to the therapeutic needs of these regions. While specific details regarding WHO prequalification are not publicly available, the company's commitment to quality and compliance with international standards likely facilitates access to these markets.

3Geographic Strategy

Unicure Remedies Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Unicure Remedies Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's export activities to regulated markets, including the United States, suggest compliance with FDA regulations and standards. The absence of publicly available information on FDA approvals indicates that the company may not have received FDA approvals for its products.

2WHO & EU GMP

Unicure Remedies Private Limited's manufacturing facility is WHO Good Manufacturing Practice (GMP) approved, indicating adherence to international quality standards. Specific details regarding EU GMP certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's commitment to quality and compliance with international standards suggests a focus on meeting the requirements of various regulatory bodies.

3CDSCO & Indian Regulatory

Unicure Remedies Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Unicure Remedies Private Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as diuretics, cardiovascular, and immunosuppressants. While specific market share comparisons are not publicly available, the company's export value of $692,000 USD and a portfolio concentration of 100% in its top five products indicate a focused approach. The company's emphasis on quality and adherence to international standards positions it to compete effectively in the global market.

2Key Differentiators

Unicure Remedies Private Limited's key differentiators include its focus on quality excellence, adherence to international standards, and a diversified product portfolio. The company's manufacturing facility is WHO GMP approved, reflecting its commitment to maintaining high-quality production processes. Additionally, the company's export activities to various international markets demonstrate its ability to meet diverse therapeutic needs globally.

3Strategic Position

Unicure Remedies Private Limited's current strategic direction focuses on the export of finished pharmaceutical formulations, including diuretics, cardiovascular drugs, and immunosuppressants. The company's adherence to international quality standards and its WHO GMP approved facility suggest a commitment to maintaining high-quality production processes. The future outlook appears to involve expanding market presence and catering to diverse therapeutic needs globally.

Buyer Due Diligence Brief — Evaluating Unicure Remedies Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Unicure Remedies Private Limited has a track record of exporting pharmaceutical formulations to various international markets, including the United States, European Union, United Kingdom, Australia, Japan, Africa, Latin America, and Southeast Asia. The company's export value of $692,000 USD and a portfolio concentration of 100% in its top five products indicate a focused approach. The absence of publicly available records of regulatory actions suggests reliability in its operations. The company's adherence to international quality standards, as evidenced by its WHO GMP approved facility, further indicates its commitment to maintaining high-quality production processes.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm the FDA approval status of specific products by checking the FDA's official database or contacting the manufacturer directly.

WHO GMP Certification: Verify the WHO GMP certification by requesting a copy of the certificate from the manufacturer or checking the WHO's official list of certified manufacturers.

Frequently Asked Questions — Unicure Remedies Private Limited

How many pharmaceutical products does Unicure Remedies Private Limited export from India?

Unicure Remedies Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Spironolactone ($518.5K), Digoxin ($82.0K), Azathioprine ($45.8K), Warfarin ($45.5K). Total export value is $691.7K.

What is Unicure Remedies Private Limited's total pharmaceutical export value?

Unicure Remedies Private Limited's total pharmaceutical export value is $691.7K, based on 73 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Unicure Remedies Private Limited cover?

Unicure Remedies Private Limited exports across 3 therapeutic categories. The largest are Diuretics (74.9%, 1 products), Cardiovascular (18.4%, 2 products), Immunosuppressants (6.6%, 1 products).

Get Full Unicure Remedies Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.